Alcaftadine
- Generic Name
- Alcaftadine
- Brand Names
- Lastacaft
- Drug Type
- Small Molecule
- Chemical Formula
- C19H21N3O
- CAS Number
- 147084-10-4
- Unique Ingredient Identifier
- 7Z8O94ECSX
- Background
Alcaftadine is a H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis. This drug was approved in July 2010.
- Indication
用于2岁以上人群过敏性结膜炎相关性眼部瘙痒的治疗。
- Associated Conditions
- Allergic Conjunctivitis (AC)
Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Allergan
- Target Recruit Count
- 3423
- Registration Number
- NCT02555761
- Locations
- 🇰🇷
Ian Eye Center, Seoul, Korea, Republic of
🇰🇷Soonchunhyang University Cheonan Hospital, Chungcheongnam-do, Korea, Republic of
🇰🇷St. Mary's Eye center, Geyonggi-do, Korea, Republic of
A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy
Phase 4
Completed
- Conditions
- Allergic Conjunctivitis
- Interventions
- Drug: Tears Naturale ® (Placebo)
- First Posted Date
- 2014-12-04
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- ORA, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT02308501
AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis
Phase 3
Completed
- Conditions
- Conjunctivitis, Allergic
- Interventions
- First Posted Date
- 2014-06-11
- Last Posted Date
- 2019-04-17
- Lead Sponsor
- Allergan
- Target Recruit Count
- 240
- Registration Number
- NCT02161146
AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis
- First Posted Date
- 2014-03-10
- Last Posted Date
- 2016-03-14
- Lead Sponsor
- Allergan
- Target Recruit Count
- 140
- Registration Number
- NCT02082262
Ocular Allergy Treatment Practical Impact Trial
- First Posted Date
- 2013-03-11
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- Starx Research Center, LLC
- Target Recruit Count
- 50
- Registration Number
- NCT01808768
- Locations
- 🇺🇸
STARx, Springfield, New Jersey, United States
🇺🇸STARx Research Center, Edison, New Jersey, United States
AGN-229666 for the Treatment of Allergic Conjunctivitis
Phase 2
Completed
- Conditions
- Allergic Conjunctivitis
- Interventions
- Other: vehicle of AGN-229666
- First Posted Date
- 2012-12-21
- Last Posted Date
- 2014-02-04
- Lead Sponsor
- Allergan
- Target Recruit Count
- 90
- Registration Number
- NCT01754766
A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis
Phase 4
Completed
- Conditions
- Conjunctivitis, Allergic
- Interventions
- First Posted Date
- 2012-11-26
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- Allergan
- Target Recruit Count
- 157
- Registration Number
- NCT01732757
A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis
Phase 4
Completed
- Conditions
- Conjunctivitis, Allergic
- Interventions
- First Posted Date
- 2011-11-11
- Last Posted Date
- 2013-02-21
- Lead Sponsor
- Allergan
- Target Recruit Count
- 127
- Registration Number
- NCT01470118
Safety and Efficacy Study of a Eye Drop for Eye Allergy
- First Posted Date
- 2009-04-28
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- Vistakon Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT00889330
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath